News

The patents relate to the company’s ability to create, develop and manufacture antibodies based on its dynamic cross linking (DXL) technology platform. The new patents name InNexus scientists

MedImmune reported the absence of serious, dose-limiting adverse events in the study and concluded that the data also demonstrated an acceptable safety profile for multiple subcutaneous doses of

The impact of this dissolution on the earnings of Daiichi Sankyo of the fiscal year ending March 2009 will be negligible, the company said. Daiichi Sankyo and Sanofi-Aventis

The special access program (SAP) provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable or are

With this agreement, Oridion becomes Kaiser’s sole supplier for Oridion’s consumable products, thus providing savings for the entire Kaiser system of hospitals and outpatient facilities. The Kaiser network

Under the research collaboration, InteRNA will apply its unique lentiviral-based miRNA overexpression library in multi-parametric, high-throughput screening assays to identify the biological role of individual miRNAs and novel

Eprotirome induced a statistically significant and clinically relevant lowering of serum low-density lipoprotein (LDL)-cholesterol, triglycerides and lipoprotein(a) and was safe and well tolerated. Data show that eprotirome in

One milestone was achieved for the start of lead optimization for a specific target. This means that for the third time within this collaboration, a program has been

This second milestone related to the start of the Fentanyl Taifun Phase III program should be followed within the next quarter by the enrollment of the first patients